Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GLYCEROL PHENYLBUTYRATE vs CARBAGLU
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Glycerol phenylbutyrate is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This compound is excreted by the kidneys, providing an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders.
Carbaglu (carbonic anhydrase inhibitor) reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes, thereby decreasing aqueous humor secretion.
Adjunctive therapy for chronic management of patients with urea cycle disorders involving deficiencies of carbamoyl phosphate synthetase I, ornithine transcarbamylase, or argininosuccinic acid synthetase. It is indicated for all patients requiring therapy for these disorders except those with arginase deficiency.
Adjunctive treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
450-600 mg/m2/day orally in three divided doses, rounded to the nearest 100 mg; maximum 20 g/day.
100 mg/kg (up to 200 mg/kg) intravenous infusion over 90 minutes, followed by 100 mg/kg/day continuous intravenous infusion; maintenance: 100 mg/kg/day oral divided into 2-4 doses, not to exceed 20 g/day.
0.8–1 hours (glycerol phenylbutyrate); 1.2–1.5 hours (phenylacetate); clinical context: short half-life requires thrice-daily dosing
Terminal half-life approximately 5.8 hours in adults; prolonged in hepatic impairment (up to 10 hours).
Glycerol phenylbutyrate is metabolized by lipases to phenylbutyrate, which is then beta-oxidized to phenylacetate. Phenylacetate conjugates with glutamine via acyl-Co A synthetase and acyl-Co A:glutamine N-acyltransferase to form phenylacetylglutamine.
Metabolized via hepatic glucuronidation and renal excretion; not extensively metabolized by CYP450 enzymes.
Renal: >90% as phenylbutyrate metabolites (mainly phenylacetylglutamine) within 24 hours; fecal: <1%
Primarily renal excretion (97% unchanged) with minimal biliary/fecal elimination (<3%).
80–90% bound to albumin (phenylacetate and phenylbutyrate)
Negligible (<1% bound to albumin or other plasma proteins).
0.2–0.3 L/kg (phenylbutyrate and metabolites); clinical meaning: primarily distributes in extracellular fluid
Vd approximately 0.3 L/kg, indicating distribution primarily in extracellular fluid.
Oral: ~100% (prodrug is completely hydrolyzed to phenylbutyrate); intraperitoneal: not used clinically
Oral bioavailability approximately 30% (range 20-40%) due to first-pass metabolism; IV bioavailability 100%.
GFR 30-59 m L/min: reduce dose by 50%; GFR 15-29 m L/min: reduce dose by 75%; GFR <15 m L/min: contraindicated.
No specific dose adjustment is provided in the manufacturer's labeling; use with caution in renal impairment. GFR <30 m L/min: consider alternative therapy.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
No specific adjustment is recommended for hepatic impairment per labeling; monitor transaminases.
450-600 mg/m2/day orally in three divided doses; for children <20 kg, use 450 mg/m2/day; maximum 20 g/day.
Loading dose: 100 mg/kg (up to 200 mg/kg) IV over 90 minutes; continuous infusion: 100-200 mg/kg/day IV or oral divided q4-6h; maximum 20 g/day.
Start at low end of dosing range (450 mg/m2/day) and titrate based on renal function and tolerability; monitor for fluid overload.
No specific adjustments; use lowest effective dose and monitor renal function given age-related decline.
None.
Sulfonamide derivative; may cause serious, potentially fatal reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and agranulocytosis. Discontinue at first sign of rash or other hypersensitivity.
Monitor plasma ammonia levels, neurotoxicity (somnolence, lethargy, confusion) due to elevated phenylacetate; caution in hepatic or renal impairment; contains phenylalanine; avoid use with valproic acid; may cause hyperammonemia if dosing is incorrect; fluid and electrolyte imbalance; growth retardation in pediatric patients; pancreatic enzyme replacement may be needed.
Sulfonamide hypersensitivity: may cause serious skin reactions and blood dyscrasias; discontinue if rash or signs of hypersensitivity occur.,May cause metabolic acidosis; use caution in patients with respiratory acidosis, diabetes, or electrolyte disturbances.,May cause drowsiness, dizziness, or blurred vision; caution when driving or operating machinery.
Known hypersensitivity to glycerol phenylbutyrate or any component; patients with arginase deficiency; patients requiring therapy for hyperammonemia who are unable to swallow capsules or have gastrointestinal obstruction.
Hypersensitivity to carbonic anhydrase inhibitors or sulfonamides,Severe renal impairment (Cr Cl <10 m L/min),Adrenocortical insufficiency (Addison's disease),Severe hepatic insufficiency
Avoid high-protein meals without concurrent nitrogen-scavenging therapy; maintain a protein-restricted diet as prescribed. Do not mix the medication with acidic foods or drinks (e.g., orange juice, tomato juice) as it can cause precipitation.
No specific food interactions; however, patients with urea cycle disorders often require protein restriction. For Carbaglu, avoid acidic beverages (e.g., fruit juice) as they may degrade the drug. Administer with water only.
Glycerol phenylbutyrate is Pregnancy Category C. No adequate studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2 times human exposure; however, fetal toxicity (reduced fetal weight, skeletal variations) occurred at maternally toxic doses. First trimester risk unknown; second and third trimesters: theoretical risk of maternal ammonia control affecting fetal development.
First trimester: Limited human data; animal studies show no increased risk of malformations. Second/third trimester: No known fetal harm; can be used for NAGS deficiency.
No data on excretion in human milk; M/P ratio unknown. Due to potential for adverse effects in nursing infants (ammonia elevation if mother has poor control), caution advised. Consider risk-benefit.
No human data; M/P ratio unknown. Use with caution.
No specific dose adjustment recommendations. Pharmacokinetics may be altered due to increased plasma volume and renal clearance; dose titration based on ammonia levels is essential. Monitor ammonia weekly initially, then as needed.
No specific dose adjustments required; monitor ammonia levels to guide therapy.
Monitor ammonia levels; glycerol phenylbutyrate is a prodrug that provides phenylbutyrate, which conjugates with glutamine to form phenylacetylglutamine, a nitrogen-scavenging agent excreted in urine. Dosing is weight-based (typically 5-12 m L/m²/day in divided doses) and must be adjusted with hepatic or renal impairment. Avoid use with probenecid as it reduces renal excretion of phenylacetylglutamine. Watch for hypernatremia and metabolic acidosis due to sodium content.
Carbaglu (carglumic acid) is a structural analog of N-acetylglutamate (NAG) and acts as a replacement therapy for N-acetylglutamate synthase (NAGS) deficiency. It is also used for hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). Monitor ammonia levels closely; therapeutic goal is normalization within 24 hours. Administer via oral or nasogastric tube; dissolve tablets in water and administer immediately. Do not mix with acidic fluids (e.g., fruit juice) as stability may be affected. May cause headaches, vomiting, and fever. For NAGS deficiency, lifelong treatment is required. For PA/MMA, use is acute and short-term. Not effective for other urea cycle disorders.
Take with food or formula to reduce gastrointestinal side effects.,Measure dose using the provided oral syringe for accuracy.,Do not mix with acidic beverages (e.g., fruit juice) as it may precipitate.,Contact physician immediately if vomiting occurs within 20 minutes of dosing.,Maintain adequate hydration to ensure urinary excretion of waste nitrogen.,Store at room temperature, do not freeze.
Take Carbaglu exactly as prescribed; do not skip doses.,Dissolve the tablet(s) in a small amount of water (2.5 m L per tablet) and drink immediately. Do not mix with juice or other acidic beverages.,If using a nasogastric tube, ensure the solution is given right after preparation.,Monitor for signs of high ammonia (e.g., lethargy, vomiting, irritability) and report to doctor immediately.,Keep all appointments for blood tests to check ammonia levels.,Store tablets at room temperature (20-25°C), away from moisture and light.,Inform your doctor of all other medications, especially valproic acid (may decrease effectiveness).
"Rimexolone, a corticosteroid with anti-inflammatory activity, may induce the metabolism of glycerol phenylbutyrate via hepatic enzyme induction, particularly CYP3A4. This reduces the conversion of glycerol phenylbutyrate to phenylacetate, decreasing therapeutic efficacy for hyperammonemia management. Clinically, patients may experience elevated ammonia levels, increasing the risk of neurotoxicity and hepatic encephalopathy."
"Concomitant administration of loteprednol, a corticosteroid, with glycerol phenylbutyrate, a nitrogen-binding agent used for urea cycle disorders, may reduce the therapeutic efficacy of glycerol phenylbutyrate. Corticosteroids are known to induce hepatic enzymes involved in drug metabolism, potentially accelerating the clearance of glycerol phenylbutyrate. This interaction could lead to increased ammonia levels and loss of disease control in patients with urea cycle disorders."
"Fluorometholone is a corticosteroid that can induce hepatic enzymes, particularly CYP3A4, potentially accelerating the metabolism of glycerol phenylbutyrate, a prodrug that relies on CYP3A4 for conversion to its active metabolite, phenylacetic acid. This reduction in systemic exposure to phenylacetic acid may decrease the therapeutic efficacy of glycerol phenylbutyrate in managing hyperammonemia in urea cycle disorders. Clinically, this could lead to elevated ammonia levels and breakthrough hyperammonemic episodes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GLYCEROL PHENYLBUTYRATE vs CARBAGLU, answered by our medical review team.
GLYCEROL PHENYLBUTYRATE is a Ammonia Detoxicant that works by Glycerol phenylbutyrate is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This compound is excreted by the kidneys, providing an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders.. CARBAGLU is a Ammonia Detoxicant that works by Carbaglu (carbonic anhydrase inhibitor) reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes, thereby decreasing aqueous humor secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GLYCEROL PHENYLBUTYRATE and CARBAGLU depend on the specific clinical indication. These are both Ammonia Detoxicant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GLYCEROL PHENYLBUTYRATE is: 450-600 mg/m2/day orally in three divided doses, rounded to the nearest 100 mg; maximum 20 g/day.. The standard adult dose of CARBAGLU is: 100 mg/kg (up to 200 mg/kg) intravenous infusion over 90 minutes, followed by 100 mg/kg/day continuous intravenous infusion; maintenance: 100 mg/kg/day oral divided into 2-4 doses, not to exceed 20 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GLYCEROL PHENYLBUTYRATE and CARBAGLU in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GLYCEROL PHENYLBUTYRATE is classified as Category C. Glycerol phenylbutyrate is Pregnancy Category C. No adequate studies in pregnant women. In animal studies, no teratogenic effects at doses up to 2 times human exposure; however, fe. CARBAGLU is classified as Category C. First trimester: Limited human data; animal studies show no increased risk of malformations. Second/third trimester: No known fetal harm; can be used for NAGS deficiency.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.